Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$25.81
-3.3%		$22.30
$16.65
▼
$29.52
$1.13B0.92526,394 shs509,071 shs
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$25.61
-3.7%		$31.16
$4.00
▼
$37.48
$1.04B1.13562,656 shs891,621 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$2.06
+2.0%		$2.34
$1.33
▼
$2.61
$281.86M0.95541,911 shs579,458 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$25.05
-2.3%		$25.30
$18.80
▼
$27.66
$1.02B0.26525,024 shs605,842 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-3.26%+3.41%+14.56%+31.42%-3.15%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-3.85%-6.81%-27.45%+3.35%+533.89%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+1.98%-4.19%-10.82%+3.52%+27.16%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-2.34%+1.71%-3.28%-1.34%-2.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$25.81
-3.3%		$22.30
$16.65
▼
$29.52
$1.13B0.92526,394 shs509,071 shs
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$25.61
-3.7%		$31.16
$4.00
▼
$37.48
$1.04B1.13562,656 shs891,621 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$2.06
+2.0%		$2.34
$1.33
▼
$2.61
$281.86M0.95541,911 shs579,458 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$25.05
-2.3%		$25.30
$18.80
▼
$27.66
$1.02B0.26525,024 shs605,842 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-3.26%+3.41%+14.56%+31.42%-3.15%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-3.85%-6.81%-27.45%+3.35%+533.89%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+1.98%-4.19%-10.82%+3.52%+27.16%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-2.34%+1.71%-3.28%-1.34%-2.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1.75
Reduce$22.50-12.82% Downside
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.64
Moderate Buy$37.2545.46% Upside
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.00
Buy$5.40162.14% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$30.1420.33% Upside

Current Analyst Ratings Breakdown

Latest IKT, AMPH, ANRO, and PCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$32.00
9/16/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
9/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$28.00
9/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/20/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/18/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$20.00 ➝ $23.00
8/17/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
8/17/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $55.00
8/17/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00
8/13/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$24.00 ➝ $26.00
8/13/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$28.00 ➝ $37.00
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$719.89M1.53$4.12 per share6.27$17.17 per share1.50
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$4.87 per shareN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$260K1,105.59N/AN/A$2.30 per share0.90
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M1.37$3.77 per share6.65$16.11 per share1.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$98.09M$1.6915.279.975.1410.76%14.98%6.96%11/5/2026 (Estimated)
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$63.24M-$2.42N/AN/AN/AN/A-46.46%-39.09%11/11/2026 (Estimated)
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$48.26M-$0.43N/AN/AN/AN/A-42.80%-40.58%N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.3571.5710.61N/A1.96%9.68%5.30%11/5/2026 (Estimated)

Latest IKT, AMPH, ANRO, and PCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.7345-$0.65+$0.0845-$0.65N/AN/A
8/11/2026Q2 2026
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$0.09-$0.11-$0.02-$0.11N/AN/A
8/6/2026Q2 2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.62$0.91+$0.29$0.67$179.92 million$183.90 million
8/4/2026Q2 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.6460$0.73+$0.0840$0.12$191.06 million$192.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.79
2.40
1.71
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.07
14.85
14.85
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
15.82
15.82
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.54
5.04
3.94

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%

Insider Ownership

CompanyInsider Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
29.60%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.25%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.10%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,97642.54 million29.95 millionOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
6839.24 million34.83 millionN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
35139.54 million129.63 millionN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
82939.86 million37.31 millionOptionable

Recent News About These Companies

Gyre Therapeutics (NASDAQ:GYRE) versus Pacira BioSciences (NASDAQ:PCRX) Financial Comparison
September 29 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31062226
240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE
September 28 at 3:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-240006-shares-in-pacira-biosciences-inc-pcrx-acquired-by-bank-of-america-corp-de-2026-09-28/
Pacira BioSciences (NASDAQ:PCRX) Stock Rating Raised to Strong-Buy at Wall Street Zen
September 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051397
Pacira BioSciences (NASDAQ:PCRX) Raised to Strong-Buy at Wall Street Zen
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-pacira-biosciences-nasdaq-pcrx-raised-to-strong-buy-at-wall-street-zen-2026-09-26/
Oppenheimer Begins Coverage on Pacira BioSciences (NASDAQ:PCRX)
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31047036
Oppenheimer initiates coverage of Pacira BioSciences with outperform
September 24, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/oppenheimer-initiates-coverage-of-pacira-biosciences-with-outperform/ar-AA2cSD0I
Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target
September 23, 2026  |  marketscreener.comM
Oppenheimer Initiates Coverage on Pacira BioSciences (NASDAQ:PCRX)
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-oppenheimer-initiates-coverage-on-pacira-biosciences-nasdaq-pcrx-2026-09-23/
Pacira BioSciences stock falls 2.35 percent to USD 24.11
September 22, 2026  |  ad-hoc-news.deA
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-pacira-biosciences-inc-nasdaq-pcrx-receives-consensus-rating-of-hold-from-brokerages-2026-09-11/
Leerink Partners initiates coverage of Pacira BioSciences at market perform
September 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/leerink-partners-initiates-coverage-of-pacira-biosciences-at-market-perform/ar-AA2bUWUO
Pacira BioSciences (NASDAQ:PCRX) Now Covered by Leerink Partners
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-pacira-biosciences-nasdaq-pcrx-now-covered-by-leerink-partners-2026-09-09/
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358566/0/en/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Public Employees Retirement System of Ohio Purchases New Position in Pacira BioSciences, Inc. $PCRX
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-purchases-new-position-in-pacira-biosciences-inc-pcrx-2026-09-09/
Wellington Management Group LLP Has $14.29 Million Holdings in Pacira BioSciences, Inc. $PCRX
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-has-1429-million-holdings-in-pacira-biosciences-inc-pcrx-2026-09-08/
Legal & General Group Plc Buys Shares of 88,640 Pacira BioSciences, Inc. $PCRX
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-buys-shares-of-88640-pacira-biosciences-inc-pcrx-2026-09-06/
296,880 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Bank of New York Mellon Corp
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-296880-shares-in-pacira-biosciences-inc-pcrx-purchased-by-bank-of-new-york-mellon-corp-2026-09-04/
Man Group plc Buys New Holdings in Pacira BioSciences, Inc. $PCRX
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-buys-new-holdings-in-pacira-biosciences-inc-pcrx-2026-09-01/
200,073 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Empowered Funds LLC
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-200073-shares-in-pacira-biosciences-inc-pcrx-acquired-by-empowered-funds-llc-2026-09-01/
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pcrx-insider-buying-and-selling-2026-08-19/
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-pcrx-quietly-reframing-061005117.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.81 -0.87 (-3.26%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$25.82 +0.02 (+0.06%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$25.61 -0.97 (-3.65%)
Closing price 09/30/2026 03:59 PM Eastern
Extended Trading
$25.56 -0.05 (-0.19%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NASDAQ:IKT

$2.06 +0.04 (+1.98%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$2.06 0.00 (-0.24%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$25.05 -0.60 (-2.34%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$25.05 0.00 (0.00%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas